References

1. 1.
   SEFEROVIĆ P M，PAULUS W J，ROSANO G，et al.Diabetic myocardial disorder.A clinical consensus statement of the heart failure association of the ESC and the ESC working group on myocardial & pericardial diseases［J］.Eur J Heart Fail，2024，26（9）：1893-1903.
2. 2.
   QUAIYOOM A，KUMAR R.An overview of diabetic cardiomyopathy［J］.Curr Diabetes Rev，2024，20（5）：e121023222139.
3. 3.
   SONG X G，CHEN Z Y，MA X，et al.Progress in role of lipotoxicity in pathogenesis of diabetic cardiomyopathy［J］.Chin J Pathophysiol，2022，38（11）：2106-2112.
4. 4.
   YANG L Q，XIE L D，ZHOU L J.Treatment of the diabetic cardiomyopathy based on the Chinese medicine viscera manifestation theory［J］.Shaanxi J Tradit Chin Med，2022，43（10）：1423-1426.
5. 5.
   QIAN H Q，NI Q，YANG W J.Diabetes-induced cardiomyopathy diagnosis and treatment guidelines （2021-12-31）［J］.World Chin Med，2022，17（12）：1641-1653.
6. 6.
   SU L Q，YU R，WU Y J，et al.Study on treatment of diabetic cardiomyopathy from theory of "persistent illness entering collaterals"［J］.J Hunan Univ Chin Med，2017，37（8）：838-841.
7. 7.
   HUANG J，WANG Y Y，XIAO FJ，et al.Mechanism of Zuogui Jiangtang Shuxin formula in inhibiting myocardial fibrosis in mice with diabetic cardiomyopathy by regulating TLR4/NF-ĸB pathway［J］.J Hunan Univ Chin Med，2024，44（5）：729-736.
8. 8.
   LIAO X Y，XIANG Q，ZOU J J，et al.The effect of Zuogui Jiangtang Shuxin formula on FoxO1/β-MHC in MKR rats with diabetic cardiomyopathy［J］.Lishizhen Med Mater Med Res，2023，34（6）：1302-1305.
9. 9.
   TIAN N，YU R，ZHANG W W，et al.Effects of Zuogui Jiangtang Shuxin recipe on autophagy on myocardial injury in diabetes transgenic MKR mice［J］.J Basic Chin Med，2023，29（5）：747-752.
10. 10.
    SU L Q，YU R，WU Y J，et al.The effect of the Zuogui Jiangtang Shuxin Formula on myocardial cell damage and apoptosis in MKR rats with diabetic cardiomyopathy［J］.Mod Tradit Chin Med Mater Med World Sci Technol，2022，24（2）：554-562.
11. 11.
    ZHANG G L，LIU Y，LIU Y F，et al.Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome［J］.World J Diabetes，2024，15（4）：724-734.
12. 12.
    ZHAO X，LIU S，WANG X，et al.Diabetic cardiomyopathy：Clinical phenotype and practice［J］.Front Endocrinol （Lausanne），2022，13：1032268.
13. 13.
    ZHANG X，YOU L Y，ZHANG Z Y，et al.Integrating pharmacological evaluation and computational identification for deciphering the action mechanism of Yunpi-Huoxue-Sanjie formula alleviates diabetic cardiomyopathy［J］.Front Pharmacol，2022，13：957829.
14. 14.
    SONG K，LIANG D，XIAO D，et al.Role of bariatric surgery in improving diabetic cardiomyopathy：Molecular mechanisms and therapeutic perspectives （Review）［J］.Mol Med Rep，2024，30（5）：199.
15. 15.
    AVAGIMYAN A，POPOV S，SHALNOVA S.The pathophysiological basis of diabetic cardiomyopathy development［J］.Curr Probl Cardiol，2022，47（9）：101156.
16. 16.
    SONG Z，WANG J，ZHANG L.Ferroptosis：A new mechanism in diabetic cardiomyopathy［J］.Int J Med Sci，2024，21（4）：612-622.
17. 17.
    SHOU Y，LI X，FANG Q，et al.Progress in the treatment of diabetic cardiomyopathy，a systematic review［J］.Pharmacol Res Perspect，2024，12（2）：e1177.
18. 18.
    FENG T.Study on the pharmacodynamic material basis of Danshen-Hawthorn pair in the treatment of ischemic heart disease ［D］.Xi'an：Air Force Military Medical University of the Chinese People's Liberation Army，2025.
19. 19.
    ZHENG W，CAO X L，DU X H，et al.Progress in the compatibility mechanism of Huangqi （Astragali Radix）［J］.J Liaoning Univ Tradit Chin Med，2023，25（10）：205-209.
20. 20.
    XUE W H，XU T L，WANG H Y，et al.Research progress of chemical composition，pharmacological action and predictive analysis of quality markers of Ophiopogon japonicus［J］.Chin Arch Tradit Chin Med，2026，doi：.
21. 21.
    LIU Q Q，FAN G W.Research progress on the modern pharmacological effects and mechanism of ginsenoside Rg₃［J］.Chin J Integr Med Cardio Cerebrovasc Dis，2022，20（13）：2375-2381.
22. 22.
    ZHANG L P，WANG P J，LI B，et al.Isolation，purification，and in vitro hypoglycemic activity of polysaccharides from Cornus officinalis［J］.Sci Technol Food Ind，2026，47（6）：60-70.
23. 23.
    FENG W S.Research progress on chemical composition and pharmacological effects of Dihuang （Rehmannia glutinosa Libosch.）［J］.Acta Chin Med，2025，40（10）：2035-2055.
24. 24.
    WU X H，XUN S J，WU W X，et al.Research progress on the chemical components and pharmacological effects of Huanglian［J］.Acta Chin Med Pharmacol，2024，52（7）：110-116.
25. 25.
    STANTON A M，VADUGANATHAN M，CHANG L S，et al.Asymptomatic Diabetic Cardiomyopathy：An underrecognized entity in type 2 diabetes［J］.Curr Diab Rep，2021，21（10）：41.
26. 26.
    WANG Y，FANG Y，VRABLIK M.Homeostasis model assessment for insulin resistance mediates the positive association of triglycerides with diabetes［J］.Diagnostics （Basel），2024，14（7）：733.
27. 27.
    ZHENG D M，AN Z N，GE M H，et al.Medium & long-chain acylcarnitine's relation to lipid metabolism as potential predictors for diabetic cardiomyopathy：A metabolomic study［J］.Lipids Health Dis，2021，20（1）：151.
28. 28.
    XU Z，QIN Y，LV B，et al.Intermittent fasting improves high-fat diet-induced obesity cardiomyopathy via alleviating lipid deposition and apoptosis and decreasing m6A methylation in the heart［J］.Nutrients，2022，14（2）：251.
29. 29.
    CAI H，CHEN S，LIU J，et al.An attempt to reverse cardiac lipotoxicity by aerobic interval training in a high-fat diet- and streptozotocin-induced type 2 diabetes rat model［J］.Diabetol Metab Syndr，2019，11：43.
30. 30.
    LIAO F J，CHEN X F，XIANG H Y，et al.Role of AMP-activated protein kinase in diabetic cardiomyopathy and its related intervention strategies［J］.Prog Biochem Biophys，2025，52（10）：2550-2567.
31. 31.
    GUO Y，XU N，MENG Q，et al.Mechanisms of Inonotus obliquus （Fr.） Pilát polysaccharides in ameliorating lipid-induced skeletal muscle insulin resistance via PI3K/Akt and AMPK/ACC1/CPT1 signaling pathways［J］.J Ethnopharmacol，2025，349：119938.
32. 32.
    LIU J，SUN Q，SUN X，et al.Therapeutic effects of salvianolic acid B on angiotensin Ⅱ-induced atrial fibrosis by regulating atrium metabolism via targeting AMPK/FoxO1/miR-148a-3p axis［J］.J Cardiovasc Transl Res，2023，16（2）：341-357.
33. 33.
    CHISTIAKOV D A，OREKHOV A N，BOBRYSHEV Y V.The impact of FOXO-1 to cardiac pathology in diabetes mellitus and diabetes-related metabolic abnormalities［J］.Int J Cardiol，2017，245：236-244.
34. 34.
    WANG S，TIAN C，GAO Z，et al.Research status and trends of the diabetic cardiomyopathy in the past 10 years （2012-2021）：A bibliometric analysis［J］.Front Cardiovasc Med，2022，9：1018841.
35. 35.
    PENG M，XIA T，ZHONG Y，et al.Integrative pharmacology reveals the mechanisms of Erzhi Pill，a traditional Chinese formulation，against diabetic cardiomyopathy［J］.J Ethnopharmacol，2022，296：115474.
36. 36.
    PHAM T K，NGUYEN T，YI J M，et al.Evogliptin，a DPP-4 inhibitor，prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice［J］.Exp Mol Med，2023，55（4）：767-778.